All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA approves isatuximab combined with carfilzomib and dexamethasone for the treatment of RRMM
By Sumayya Khan
On March 31, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of isatuximab (Isa) in combination with carfilzomib plus dexamethasone (Kd) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received 1–3 prior lines of therapy. This approval was based on results of the phase III IKEMA trial (NCT03275285), which were previously published on the Multiple Myeloma Hub and showed a 45% reduction in the risk of disease progression or death with Isa-Kd compared with Kd alone (HR, 0.548; 95% CI, 0.366–0.822; p = 0.0032).1
This Isa-Kd combination has also recently received a positive opinion by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for adult patients with MM previously treated with ≥1 line of therapy.
- Sanofi. FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. https://www.sanofi.com/en/media-room/press-releases/2021/2021-03-31-23-15-00-2202919. Published Mar 31, 2021. Accessed Apr 1, 2021.
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox